Evaxion Biotech A/S (EVAX) |
|
2.91 0.48 (19.75%)
|
09-24 16:32 |
|
Open: |
2.4 |
Pre. Close: |
2.43 |
|
High:
|
3.0682 |
Low:
|
2.2917 |
|
Volume:
|
1,093,718 |
Market Cap:
|
70(M) |
|
|
|
|
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.07 - 3.09 |
3.09 - 3.1 |
|
Low:
|
2.27 - 2.28 |
2.28 - 2.29 |
|
Close:
|
2.89 - 2.91 |
2.91 - 2.93 |
|
Technical analysis |
as of: 2022-09-23 4:23:54 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 4.11  One year: 4.8 |
| Support: |
Support1: 2.51 Support2: 1.89 |
| Resistance: |
Resistance1: 3.51 Resistance2: 4.11 |
| Pivot: |
2.15 |
| Moving Average: |
MA(5): 2.3 MA(20): 2.2
MA(100): 2.24 MA(250): 3.56  |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 40.5 %D(3): 23.4 |
| RSI: |
RSI(14): 68.6 |
| 52-week: |
High: 25.04 Low: 1.5 |
| Average Vol(K): |
3-Month: 827 (K) 10-Days: 4,787 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVAX ] has closed Bollinger Bands are 26.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 23 Sep 2022
Healthcare Stocks Moving Up and Down Friday: ATHX, CO, XRTX, EVAX, ATXI, AORT, CWBR, CASI - InvestorsObserver
Thu, 22 Sep 2022
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - InvestorPlace
Thu, 22 Sep 2022
It is Poised to be a Bull Market for Evaxion Biotech A/S (EVAX) - SETE News
Thu, 22 Sep 2022
Good Penny Stocks to Add to Your Buy List? 3 to Watch - StreetInsider.com
Wed, 21 Sep 2022
Health Care Sector Update for 09/21/2022: EVAX,VTRS,OMCL,SHC - Nasdaq
Wed, 21 Sep 2022
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.70% By Investing.com - Investing.com UK
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
24 (M) |
| Shares Float |
14 (M) |
|
% Held by Insiders
|
42.8 (%) |
|
% Held by Institutions
|
0.9 (%) |
|
Shares Short
|
195 (K) |
|
Shares Short P.Month
|
203 (K) |
Stock Financials |
|
EPS
|
-1.26 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.85 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-53.3 |
|
Return on Equity (ttm)
|
-115.2 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.1 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-24 (M) |
|
Levered Free Cash Flow
|
-15 (M) |
Stock Valuations |
|
PE Ratio
|
-2.32 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.42 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.92 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
